Raffaele Carrano^1,#, Carlotta Zucca^1,#, Nicla Cristina¹, Martina Grande¹, Eleonora Leti Maggio¹, Riccardo Bei², Antonio Infante², Chiara Focaccetti¹, Valeria Lucarini³, Loredana Cifaldi¹, Laura Masuelli⁴, Luciano Mutti⁵, Camilla Palumbo¹, Monica Benvenuto¹, Roberto Bei^1,*

Oncology Research, Vol.33, No.9, pp. 2181-2204, 2025, DOI:10.32604/or.2025.066708 - 28 August 2025

Abstract Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent advances, conventional treatment approaches remain largely ineffective due to late diagnosis, chemoresistance and immunosuppressive tumor microenvironment. This review reports the latest studies on combination therapies for mesothelioma, focusing on the potential of integrating chemotherapeutic agents, molecularly targeted agents, vaccines and natural bioactive compounds such as polyphenols. Clinical and preclinical studies demonstrate that integrating immune-modulating drugs or molecular inhibitors with chemotherapy can improve survival and reduce tumor progression in mesothelioma models and patients. Vaccine-based strategies show potential for inducing More > Graphic Abstract

MARTA SANTOS¹, DIANA MARTINS^1,2,3,4, FERNANDO MENDES^1,2,3,4,5,*

Oncology Research, Vol.33, No.2, pp. 263-281, 2025, DOI:10.32604/or.2024.052207 - 16 January 2025

Abstract Background: Gastric Cancer (GC) is the 5th most prevalent and 4th most deadly neoplasm globally. Immunotherapy has emerged as a promising treatment approach in GC, potentially improving positive clinical outcomes while addressing the limitations of conventional therapies. GC immunotherapy modalities consist of adoptive cell therapy (ACT), cancer vaccines, and immune checkpoint inhibitors (ICI). Objectives: This systematic review aims to provide an overview of the advances in immune-based therapeutic approaches in GC, highlighting the potential of this therapy as a strategy for GC treatment. Methods: Key studies investigating several immunotherapeutic agents and combination therapies were searched in… More > Graphic Abstract

Alvaro Morales

Canadian Journal of Urology, Vol.24, No.3, pp. 8788-8793, 2017

Abstract Introduction: It is 40 years since the initial documentation of the efficacy of bacille Calmette-Guérin (BCG) in the management of non-muscle invasive bladder cancer (NMIBC) and probably an opportune a time as any to retrace the origins of this development and to reflect on the progress that has occurred on the use of immune modifiers in the treatment of NMIBC.
Materials and methods: A PubMed search for publications on the history of BCG was conducted, and those related to the development of the vaccine for protection against tuberculosis as well as those published in the last 40… More >